BOLD (Boundless Bio) Accounts Payable : $2.54 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Accounts Payable?

Boundless Bio's Accounts Payable for the quarter that ended in Sep. 2024 was $2.54 Mil.

Boundless Bio's quarterly Accounts Payable declined from Mar. 2024 ($2.94 Mil) to Jun. 2024 ($1.69 Mil) but then increased from Jun. 2024 ($1.69 Mil) to Sep. 2024 ($2.54 Mil).

Boundless Bio's annual Accounts Payable increased from Dec. 2021 ($1.08 Mil) to Dec. 2022 ($1.40 Mil) and increased from Dec. 2022 ($1.40 Mil) to Dec. 2023 ($2.22 Mil).

Boundless Bio Accounts Payable Historical Data

The historical data trend for Boundless Bio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Accounts Payable Chart

Boundless Bio Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable

1.08

1.40

2.22

Boundless Bio Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Payable	Get a 7-Day Free Trial						0.81	2.22	2.94	1.69	2.54

Boundless Bio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Boundless Bio Accounts Payable Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121

Website

https://www.boundlessbio.com

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.